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Background: Haemophilus inﬂuenzae causes community-
acquired respiratory tract and invasive infections in humans.
Resistance to macrolides and ﬂuoroquinolones is emerging in H.
inﬂuenzae limiting its therapeutic options. In the present study we
demonstrated in vitro and in vivo potential of this novel ketolide
against H. inﬂuenzae.
Methods&Materials:MIC of fresh clinical isolates ofH. inﬂuen-
zae (n=145) (- lactamase producer, non-producer strains and
standard ATCC quality control strains) from tertiary care centers in
India was evaluated using microbroth dilution method (CLSI). Bac-
tericidal potential was evaluated using time kill kinetics method
against 3 strains. Immunocompromised mouse and rat pneumonia
model were performed against 2 clinical isolates of H. inﬂuen-
zae. Plasma and ELF concentrations were estimated using standard
HPLC analysis and Microbiological method.
Results: Ketolide A showed MIC range of 0.03 - 4g/ml against
fresh clinical isolates of H. inﬂuenzae. Ketolide A was bactericidal
against 3 different strains of H. inﬂuenzae at 4X MIC concentration
and the results were comparable with telithromycin. Ketolide A
showed>1 log10 reduction in theCFU/lungs compared to2hcontrol
at 100 mg/kg BW PO bid in rat and mouse immunocompromised
pulmonary infection models. The efﬁcacy of ketolide A correlated
with its accumulation in rat lung tissue much above its MIC levels
(1-2g/ml) upto 8h.
Conclusion: Efﬁcacy of ketolideA in rodentH. inﬂuenzaemodels
and high concentration in ELF and lung tissue warrants its further
investigation for the treatment of H. inﬂuenzae infections.
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Synthesis and antibacterial activity of novel
3’-N-alkyl ketolide and ﬂuoro-ketolide
carbamates against community acquired
respiratory pathogens
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Background:Macrolidesused inclinic areassociatedwithnum-
ber of shortcomings. Our research efforts were directed towards
identiﬁcation of novel macrolides that will address these issues.
Methods & Materials: We report herein, modiﬁcations at 3’-N
and C-2 position of the macrolide ring system. A series of ketolides
and 2-ﬂuoro-ketolides 11, 12-cyclic carbamates in which one of
the methyl of the 3’-N,N-dimethyl group was replaced by the
other alkyl group were synthesized and evaluated against relevant
macrolide-sensitive andmacrolide resistant respiratorypathogens.
Results: Excellent in-vitro activities with MIC range of 0.008-
0.125 against gram positive S.pneumoniae and 0.06 - 16g/ml
against macrolide resistant S.pneumoniae strains were demon-
strated for someof theC2-ﬂuoroketolides. Fewof themalso showed
excellent activity against S aureus and S. pyogenes strains. Modula-
tion of the activity was also observed with modiﬁcation on 3’-N
position.
Conclusion: We have synthesized novel series of ketolide and
C2-ﬂuoroketolide antibiotics that exhibited good in-vitro activity
against the macrolide resistant pathogens including lab generated
telithromycin resistant S.pneumoniae strains. Moreover, the struc-
ture activity relationship study of these compounds led to the
discovery of a novel ﬂuoroketolide lead.
http://dx.doi.org/10.1016/j.ijid.2016.02.322
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Pharmacokinetic endeavors for antimalarial
therapeutics
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Background: The pharmacokinetic compatibility of short-
actingCDRI candidate antimalarial trioxanederivative, 99-411,was
